Bristol-Myers Squibb Co. (BMY) said that it has received FDA approval to market Abilify for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
While there is no approved treatment for the core symptoms of autistic disorder, irritability can be an associated behavior of autistic disorder and is manifested as aggression towards others, deliberate self-injurious behaviors, temper tantrums, aggression and quickly changing moods.
Behavioral problems such as irritability can be a source of impairment or distress to an individual with autistic disorder.
Otsuka Pharmaceutical Co. Ltd. and Bristol-Myers Squibb are collaborative partners in the development and commercialization of Abilify in the United States and major European countries.
by RTT Staff Writer
For comments and feedback: email@example.com